

January 2, 2025

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
--------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sub: Regulations 30 and 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”) and outcome of the meeting of the Securities Issue and Allotment Committee of the Board of Directors of Camlin Fine Sciences Limited (the “Company”) held on January 2, 2025.

Dear Sir/Madam,

This is further to the meeting of the Board of Directors of the Company (the “**Board**”) held on November 22, 2024, approving the issuance of equity shares of the Company (the “**Rights Equity Shares**”) for an amount not exceeding ₹225 crore, by way of a rights issue (“**Rights Issue**”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, other applicable laws and our prior intimation dated December 30, 2024.

Pursuant to the above referred, we wish to inform you that the Securities Issue and Allotment Committee of the Board at its meeting held today, i.e. on Thursday, January 2, 2025, has *inter alia* considered and approved the following terms of the Rights Issue:

- a) **Total number of Rights Equity Shares and Rights Issue size:** 2,04,26,244 Rights Equity Shares each for an amount aggregating upto ₹224,68,86,840/- (assuming full subscription).
- b) **Rights Issue Price:** ₹110 per Rights Equity Share (including a premium of ₹109) per Rights Equity Share)
- c) **Record date:** Wednesday, January 8, 2025
- d) **Rights Issue period:**
 - i. Rights Issue Opening Date: Friday, January 17, 2025;
 - ii. Rights Issue Closing Date: Monday, January 27, 2025;
 - iii. On-market renunciation period: Friday, January 17, 2025, to Thursday, January 23, 2025;
 - iv. Off-market renunciation: It is noted that the eligible equity shareholders will have to ensure that renunciation through off-market transfers is completed in such a manner that the rights entitlements are credited to the demat account of the Renouncee on or prior to the Issue Closing Date.

 **Registered Office:**
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfs.com

 www.camlinfs.com

e) Outstanding Equity Shares:

- i. Prior to the Rights Issue: 16,74,95,207 equity shares of the Company.
- ii. Post Rights Issue#: 18,79,21,451 equity shares of the Company.
#Assuming full subscription.

f) Other terms of the Rights Issue: To be included in the Letter of Offer to be filed by the Company.

g) Rights entitlement ratio and fractional entitlements: The Rights Equity Shares are being offered on a rights basis to Eligible Equity Shareholders in the ratio of 5 (Five) Equity Share(s) for every 41 (Forty-One) Equity Shares held on the Record Date.

For Equity Shares being offered on a rights basis under this Issue, if the shareholding of any of the Eligible Equity Shareholders is less than 41 (Forty-One) Equity Shares or not in the multiple of 41 (Forty-One), the fractional entitlement of such Eligible Equity Shareholders shall be ignored in the computation of the Rights Entitlement. However, the Eligible Equity Shareholders whose fractional entitlements are being ignored, will be given preferential consideration for the allotment of one additional Equity Share each if they apply for additional Equity Shares over and above their Rights Entitlement, if any, subject to availability of Rights Equity Shares in this Issue post allocation towards Rights Entitlements applied for.

Further, the Eligible Equity Shareholders holding less than 41 (Forty-One) Equity Shares as on Record Date shall have 'zero' entitlement in the Issue. Such Eligible Equity Shareholders are entitled to apply for additional Equity Shares and will be given preference in the allotment of one additional Equity Share if, such Eligible Equity Shareholders apply for the additional Equity Shares. However, they cannot renounce the same in favour of third parties and the application forms shall be non-negotiable.

h) ISIN for Rights Entitlement: INE052I20016

The meeting of the Securities Issue and Allotment Committee commenced at 02:00 p.m. and concluded at 02:45 p.m.

We request you to take the aforesaid on records.

Thanking you,
Yours faithfully,

For Camlin Fine Sciences Limited

Rahul Sawale
Company Secretary
& V. P. Legal



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com